STRATEGIC ALLIANCE AGREEMENT BY AND BETWEEN INFINITY PHARMACEUTICALS, INC. AND MUNDIPHARMA INTERNATIONAL CORPORATION LIMITEDStrategic Alliance Agreement • March 13th, 2009 • Infinity Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Infinity’s Hsp90 inhibitor program, comprising IPI-504 (retaspimycin hydrochloride), which is in an international Phase 3 registration trial for patients with refractory gastrointestinal stromal tumors (the RING trial), and IPI-493, Infinity’s oral candidate currently in a Phase 1 study in patients with advanced solid tumors, remains partnered with AstraZeneca and is excluded from this alliance. Infinity’s program targeting the Bcl family of proteins, which was transitioned to Novartis in February of 2008, is also excluded from this alliance.
STRATEGIC ALLIANCE AGREEMENT BY AND BETWEEN INFINITY PHARMACEUTICALS, INC. AND PURDUE PHARMACEUTICAL PRODUCTS L.P.Strategic Alliance Agreement • March 13th, 2009 • Infinity Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Strategic Alliance Agreement (the “Agreement”) is entered into as of the 19 th day of November 2008 (the “Effective Date”) by and between Infinity Pharmaceuticals, Inc., a Delaware corporation having its principal office at 780 Memorial Drive, Cambridge, Massachusetts 02139 (“Infinity”), and Purdue Pharmaceutical Products L.P., a Delaware limited partnership having its principal office at One Stamford Forum, 201 Tresser Boulevard, Stamford, Connecticut 06901-3431 (“Purdue”).
